Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 282

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Reduced oxidative damage in ALS by high‐dose enteral melatonin treatment

Open access
Weishaupt, Jochen H., Bartels, Claudia, Pölking, Esther, Dietrich, Jeannine, Rohde, Gundula, Poeggeler, Burkhard, Mertens, Nina, Sperling, Swetlana, Bohn, Matthias, Hüther, Gerald, Schneider, Armin, Bach, Alfred, Sirén, Anna‐Leena, Hardeland, Rüdiger, Bähr, Mathias, Nave, Klaus‐Armin, Ehrenreich, Hannelore·2006·Journal of Pineal Research

Abstract

Abstract: Amyotrophic lateral sclerosis (ALS) is the collective term for a fatal motoneuron disease of different etiologies, with oxidative stress as a common molecular denominator of disease progression. Melatonin is an amphiphilic molecule with a unique spectrum of antioxidative effects not conveyed by classical antioxidants. In preparation of a possible future clinical trial, we explored the potential of melatonin as neuroprotective compound and antioxidant in: (1) cultured motoneuronal cells (NSC‐34), (2) a genetic mouse model of ALS (SOD1 G93A‐transgenic mice), and (3) a group of 31 patients with sporadic ALS. We found that melatonin attenuates glutamate‐induced cell death of cultured motoneurons. In SOD1 G93A‐transgenic mice, high‐dose oral melatonin delayed disease progression and extended survival. In a clinical safety study, chronic high‐dose (300 mg/day) rectal melatonin was well tolerated during an observation period of up to 2 yr. Importantly, circulating serum protein carbonyls, which provide a surrogate marker for oxidative stress, were elevated in ALS patients, but were normalized to control values by melatonin treatment. This combination of preclinical effectiveness and proven safety in humans suggests that high‐dose melatonin is suitable for clinical trials aimed at neuroprotection through antioxidation in ALS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-079x.2006.00377.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 282

Metadata

Authors
Weishaupt, J. H., Bartels, C., Pölking, E., Dietrich, J., Rohde, G., Poeggeler, B., Mertens, N., Sperling, S., Bohn, M., Hüther, G., Schneider, A., Bach, A., Sirén, A., Hardeland, R., Bähr, M., Nave, K., & Ehrenreich, H.
Venue
Journal of Pineal Research
Publisher
Wiley
Published
2006-08-29
Volume
41
Issue
4
Pages
313-323
ISSN
  • 0742-3098 (ISSN-L)
  • 1600-079X
OpenAlex
W2113208927
Cited by
282
References
6
FWCI
6.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduced oxidative damage in ALS by high‐dose enteral melatonin treatment. https://app.cochat.ai/papers/10.1111/j.1600-079x.2006.00377.x
The paper
Weishaupt, J. H., Bartels, C., Pölking, E., Dietrich, J., Rohde, G., Poeggeler, B., Mertens, N., Sperling, S., Bohn, M., Hüther, G., Schneider, A., Bach, A., Sirén, A., Hardeland, R., Bähr, M., Nave, K., & Ehrenreich, H. (2006). Reduced oxidative damage in ALS by high‐dose enteral melatonin treatment. Journal of Pineal Research. https://doi.org/10.1111/j.1600-079x.2006.00377.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.